Abrocitinib leads to recapture of efficacy rates after atopic dermatitis flares

Optimizing asthma adherence with EMM

Epidemiology and management of FPIES

Tezepelumab leads to sustained reduction of inflammatory biomarkers through 52 weeks

Lower type 2 inflammation biomarkers in adult and adolescent EoE patients treated with dupilumab

Benralizumab significantly reduces asthma exacerbations: ZEPHYR 2 study